Abstract:Introduction Short-chain fatty acids (SCFA) are bacterial metabolites that, within microbiome-gut-brain axis, make a promising research line on etiopathology of mental diseases like schizophrenia (SZ) and major depression disorder. Besides, depressive symptoms are frequent clinical features of SZ. Objectives - Describe fecal SCFA concentrations in SZ patients. - Analyze differences in SCFA depending on: - Depression. - Clinical severity, antipsychotics and antidepressants, comorbidities (pro-inflammatory state/obesity/metabolic syndrome [MetS]), lifestyle. Methods Cross-sectional study of 67 outpatients [mean age=43.52±12.42, range=22-67; males=40 (59.7%)] with diagnosis (DSM-5) of SZ recruited from their mental health clinics in Oviedo (Spain). - Assessment: - Fecal SCFA (gas chromatography;μg/mL). - Plasmatic C-reactive protein (CPR;mg/dL). - PANSS, Calgary Depression (CDS), International Physical Activity (IPAQ), Mediterranean Diet Adherence (MEDAS). - Toxic habits (alcohol use/smoking/cannabis). - Chlorpromazine equivalent doses (CPZ-ED), use of antidepressants. - MetS (ATP-III), body mass index (BMI; kg/cm2). - Statistics: Spearman correlation, U Mann-Whitney, ANCOVA. Results 14 patients showed clinical depression (CDS≥5). There were no differences in age or sex between groups. 36 patients (53.7%) showed systemic low-grade inflammation (CPR≥0.3mg/dL) and 32 (30.8%) MetS.Table 1 shows fecal SCFA levels by depressive state. Means (SD) are ahown. Table 1 CDS≤4 CDS≥5 Total U Mann-Whitney (p-value) Acetate 21.449(12.823) 12.911(7.189) 19.665(12.328) 221.000(0.021) Propanoate 9.170(6.819) 6.848(6.036) 8.685(6.687) 268.500(0.114) Butyrate 8.529(6.436) 7.875(8.232) 8.392(6.787) 320.000(0.432) Total SCFA 39.148(23.770) 31.415(24.526) 36.742(23.549) 250.000(0.062) Correlations were found in Age with Butyrate (r=-0.248,p=0.043) and weekly alcohol units with Propanoate (r=0.250,p=0.041) plus trend to significance with Butyrate (r=0.232,p=0.059). It also showed a trend towards statistical relation for CPZ-ED with Propanoate (r=-0.253,p=0.039) and Total SCFA (r=-0.253,p=0.039). We found no correlation in SCFA with MetS, CGI, PANSS-N, BMI, IPAQ, MEDAS and other toxic habits. ANCOVA was performed to Acetate and Total SCFA using depression state as independent variable and Age and CPZ-ED as covariates. There was a trend towards statistical significance for Acetate (F=3.937,p=0.052,η2=0.059) whereas Total SCFA showed no difference (F=1.350,p=2.250,η2=0.021). Conclusions There seems to be lower levels of fecal Acetate in SZ patients with depressive symptoms, considering age and antipsychotic intake. In our sample there was no relation between SFCA and clinical severity, lifestyle, comorbidities or antidepressant use. Disclosure of Interest None Declared

Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort

Sexual function in outpatients with depressive disorder

Gender specific sexual dysfunction in patients with depression

The low frequency of reported sexual dysfunction in Asian patients with schizophrenia (2001-2009): low occurrence or ignored side effect?

Sexual Dysfunction in Chronically Medicated Male Inpatients With Schizophrenia: Prevalence, Risk Factors, Clinical Manifestations, and Response to Sexual Arousal

Short-chain fatty acids in schizophrenia: are they affected by a depressive state?

Sexual dysfunction in patients with neuromyelitis optica spectrum disorder

Prevalence and Associated Factors of Sexual Dysfunction in Patients with Inflammatory Bowel Disease

Prevalence of Sexual Dysfunction and Its Association with Psychological Symptoms in Drug-Naive Major Depressive Disorder Patients in West China

Prevalence of sexual dysfunction in Chinese patients with schizophrenia: a systematic review and meta-analysis

Relationship Between Sexual Dysfunction and Quality of Life in Psychiatric Patients Receiving Regular Treatment: A Cross-Sectional Study

Systemic immune-inflammatory index and its association with female sexual dysfunction, specifically low sexual frequency, in depressive patients: Results from NHANES 2005 to 2016

Improving the Sexual Wellbeing of Patients with Psychotic Illness

Profiles of University Students in Terms of Sexual Dysfunction: The Role of Anxiety, Depression, Eating Attitudes, and Mindfulness.

Sexual Dysfunction among Reproductive-Aged Chinese Married Women in Hong Kong: Prevalence, Risk Factors, and Associated Consequences.

Female Sexual Dysfunction: Prevalence and Risk Factors

Sexual dysfunction in male schizophrenia: Influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes

Exploring depression in people with schizophrenia spectrum disorders: A cross-sectional analysis of the clinical relationship with Positive and Negative Syndrome Scale dimensions

- Individuals with major depressive disorder and inflammation exhibited sex hormone imbalance: new insights from the Biomarker in Depression (BIODEP) study

A Real-World Study on Antidepressant-Associated Sexual Dysfunction in 2144 Outpatients: The SALSEX I Study

Investigation on the prevalence and risk factors of female sexual dysfunction (FSD) among Chinese urban women in Chengdu